← All trials
NCT02687841
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2016
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 206
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Taiwan UniversityLead sponsor
- Taoyuan General HospitalOverall official - principal investigator
- Chang Gung UniversityOverall official - principal investigator
- National Taiwan UniversityOverall official - principal investigator
- Taipei Medical UniversityOverall official - principal investigator
- National Taiwan UniversityReponsible party - principal investigator
- Taoyuan General HospitalCollaborator
- Taipei Medical UniversityCollaborator
- National Taiwan UniversityCollaborator
- Chang Gung UniversityCollaborator
- China Medical UniversityCollaborator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.